{"id":"bpal-m-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The regimen combines four anti-tuberculosis agents with complementary mechanisms: bedaquiline inhibits ATP synthase, pretomanid is a prodrug activated by mycobacterial enzymes to disrupt cell wall synthesis, linezolid inhibits protein synthesis, and moxifloxacin inhibits DNA gyrase. This multi-target approach is designed to treat drug-resistant tuberculosis, particularly extensively drug-resistant (XDR-TB) and multidrug-resistant (MDR-TB) strains.","oneSentence":"BPaL(M) is a combination regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin that targets multiple pathways in Mycobacterium tuberculosis to overcome drug resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:28:09.958Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Extensively drug-resistant tuberculosis (XDR-TB)"},{"name":"Multidrug-resistant tuberculosis (MDR-TB)"}]},"trialDetails":[{"nctId":"NCT05381194","phase":"PHASE4","title":"BPaL(M) Regimen for the Treatment of MDR/RR-TB","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-12-13","conditions":"Multidrug- and Rifampicin-resistant Tuberculosis","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bedaquiline, Pretomanid, Linezolid, Moxifloxacin"],"phase":"marketed","status":"active","brandName":"BPaL(M) regimen","genericName":"BPaL(M) regimen","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BPaL(M) is a combination regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin that targets multiple pathways in Mycobacterium tuberculosis to overcome drug resistance. Used for Extensively drug-resistant tuberculosis (XDR-TB), Multidrug-resistant tuberculosis (MDR-TB).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}